Related Experiment Video
Updated: Sep 18, 2025

Using Unidirectional Rotations to Improve Vestibular System Asymmetry in Patients with Vestibular Dysfunction
Published on: August 30, 2019
Sodium Channel Blockers for Vestibular Paroxysmia in Children
Pierre Reynard1,2, Hung Thai-Van1,2,3, Eugenia Mustea1
1Department of Audiology and Otoneurological Explorations, Civil Hospitals of Lyon, 69003 Lyon, France.
Insights
Vestibular paroxysmia (VP) in children is a treatable cause of vertigo. Sodium channel blockers like oxcarbazepine and carbamazepine show promising results, offering fast relief for pediatric patients.
Area of Science:
- Neurology
- Pediatrics
- Otolaryngology
Background:
- Vestibular paroxysmia (VP) is increasingly recognized in children, accounting for up to 4% of pediatric vertigo cases.
- A positive therapeutic response to sodium-channel-blocking drugs has been observed in pediatric VP.
Purpose of the Study:
- To review the current literature on vestibular paroxysmia in children.
- To provide guidance on the diagnosis and treatment of pediatric VP.
Main Methods:
- A comprehensive literature search was conducted using PubMed, Medline, Cochrane, and Crossref databases.
- Studies focusing on VP in children and the use of sodium channel blockers were selected for review.
Main Results:
- Limited evidence exists, with only five articles (case series/reports) identified.
- Oxcarbazepine (300-360 mg/day) and carbamazepine (50-200 mg/day) are the primary treatments, with efficacy reported within one week.
- Treatment duration typically spans six weeks.
Conclusions:
- Vestibular paroxysmia is a recognized condition in pediatric patients.
- Sodium channel blockers appear effective for pediatric VP, mirroring adult responses.
- Increased awareness is crucial for identifying this treatable cause of episodic vertigo in children.
Abstract:
Background/Objectives: As vestibular paroxysmia (VP) has recently been described in children, with an incidence of up to 4% of vertigo, and a promising therapeutic response to sodium-channel-blocking drugs has also been reported, the aim of this paper is to review the available literature on this topic and to provide the best possible guidance for diagnosis and treatment. Methods: PubMed, Medline, Cochrane, and Crossref databases were searched, and all studies on VP in children and sodium channel blockers were selected. Results: Only five articles reporting small case series or single case reports were identified. To date, oxcarbazepine (OXC) and carbamazepine (CBZ) are the only two molecules prescribed. The recommended doses were 300 to 360 mg/day and 50 to 200 mg/day for OXC and CBZ, respectively, for a total duration of 6 weeks. Fast efficacy (one week) was reported. Conclusions: VP has been identified in pediatric patients and appears to respond to sodium channel blockers in a manner similar to adults. Only a limited number of cases have been reported to date; thus, there is a need to raise awareness about this treatable cause of episodic vertigo in children.
More Related Videos
Related Concept Videos
Equilibrium and Balance
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
The Vestibular System

